BioAtla (BCAB) Competitors $0.80 -0.03 (-3.05%) Closing price 04:00 PM EasternExtended Trading$0.78 -0.01 (-1.26%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. CTOR, ZURA, TVGN, MOLN, NVCT, CYBN, CRBP, BTMD, NKTX, and SAVAShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Citius Oncology (CTOR), Zura Bio (ZURA), Tevogen Bio (TVGN), Molecular Partners (MOLN), Nuvectis Pharma (NVCT), Cybin (CYBN), Corbus Pharmaceuticals (CRBP), biote (BTMD), Nkarta (NKTX), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Its Competitors Citius Oncology Zura Bio Tevogen Bio Molecular Partners Nuvectis Pharma Cybin Corbus Pharmaceuticals biote Nkarta Cassava Sciences BioAtla (NASDAQ:BCAB) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability. Do analysts rate BCAB or CTOR? Citius Oncology has a consensus price target of $6.00, indicating a potential upside of 219.15%. Given Citius Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Citius Oncology is more favorable than BioAtla.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals and insiders have more ownership in BCAB or CTOR? 77.2% of BioAtla shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 11.2% of BioAtla shares are held by company insiders. Comparatively, 6.7% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, BCAB or CTOR? BioAtla has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 2.92, indicating that its stock price is 192% more volatile than the S&P 500. Does the media refer more to BCAB or CTOR? In the previous week, Citius Oncology had 2 more articles in the media than BioAtla. MarketBeat recorded 4 mentions for Citius Oncology and 2 mentions for BioAtla. BioAtla's average media sentiment score of 0.99 beat Citius Oncology's score of 0.89 indicating that BioAtla is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Oncology 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BCAB or CTOR more profitable? Citius Oncology's return on equity of -51.93% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -1,177.18% -137.51% Citius Oncology N/A -51.93%-22.17% Which has preferable valuation and earnings, BCAB or CTOR? Citius Oncology has lower revenue, but higher earnings than BioAtla. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M4.24-$69.78M-$1.10-0.72Citius OncologyN/AN/AN/AN/AN/A SummaryCitius Oncology beats BioAtla on 7 of the 11 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.15M$3.32B$6.10B$10.53BDividend YieldN/A2.29%5.51%4.66%P/E Ratio-0.7221.5485.6826.85Price / Sales4.24428.14584.82185.94Price / CashN/A46.3226.3031.10Price / Book3.1810.0613.256.72Net Income-$69.78M-$52.22M$3.30B$276.44M7 Day Performance15.57%5.84%4.70%3.13%1 Month Performance48.18%12.05%8.43%10.21%1 Year Performance-63.02%26.13%88.01%40.35% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla0.7144 of 5 stars$0.80-3.0%N/A-62.7%$48.15M$11M-0.7260Gap UpCTORCitius Oncology3.3241 of 5 stars$2.03+1.5%$6.00+195.6%+57.1%$156.74MN/A0.00N/ANews CoverageZURAZura Bio3.1408 of 5 stars$2.99+24.1%$11.60+288.0%-4.8%$156.69MN/A-4.273High Trading VolumeTVGNTevogen Bio2.3472 of 5 stars$0.79-1.1%$10.00+1,169.7%+132.5%$156.64MN/A-4.153MOLNMolecular Partners1.1096 of 5 stars$3.74-2.9%$8.00+113.9%-25.9%$155.32M$681K-1.80180Positive NewsNVCTNuvectis Pharma2.6549 of 5 stars$5.92-2.6%$15.33+159.0%-0.8%$154.78MN/A-5.068CYBNCybinN/A$5.99+2.2%$85.00+1,319.0%N/A$150.88MN/A-1.3750CRBPCorbus Pharmaceuticals4.0221 of 5 stars$12.26+1.2%$45.43+270.5%-24.4%$148.41MN/A-2.5840Positive NewsBTMDbiote2.3448 of 5 stars$2.99flat$6.00+100.7%-43.3%$147.82M$199.07M3.32194NKTXNkarta2.3348 of 5 stars$2.07+1.5%$13.60+557.0%-45.2%$144.89MN/A-1.40140SAVACassava Sciences2.8351 of 5 stars$3.14+5.0%$2.00-36.3%-86.8%$144.44MN/A-1.2330News Coverage Related Companies and Tools Related Companies CTOR Alternatives ZURA Alternatives TVGN Alternatives MOLN Alternatives NVCT Alternatives CYBN Alternatives CRBP Alternatives BTMD Alternatives NKTX Alternatives SAVA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
